Cartography Biosciences Announces Strategic Investment From Samsung Ventures to Advance Oncology Pipeline
Cartography Biosciences and Samsung Ventures today announced a strategic investment to support the advancement of Cartography’s differentiated oncology pipeline and expand its proprietary drug discovery platform.
Cartography Announces Appointments of Four Industry and Academic Leaders to its Clinical Advisory Board
Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of four new members to its Clinical Advisory Board (CAB). The new members include Kristen Hege M.D., Former SVP, Early Clinical Development, Hematology/Oncology & Cell Therapy at Bristol-Myers Squibb (BMS); Bridget Keenan M.D., Ph.D., Assistant Professor at University of California, San Francisco, Dirk Nagorsen, M.D., Chief Medical Officer at Affini-T Therapeutics and, Josep Tabernero, M.D., Ph.D., Head of the Medical Oncology Department at the Vall d´Hebron University Hospital in Barcelona.
Cartography Biosciences Expands Leadership Team with Appointment of Dan Rock, Ph.D., as Chief Scientific Officer to Advance Novel Oncology Programs into Clinic
Cartography Biosciences, an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Dan Rock, Ph.D., as Chief Scientific Officer. In this role, Dr. Rock will be responsible for guiding the company’s scientific strategy and leading efforts to advance Cartography’s internal programs into the clinic.
Cartography Biosciences Expands Scientific Advisory Board with Leading Antibody and Bi-specific Experts
Cartography Biosciences, an immuno-oncology company creating biologic therapies against novel targets guided by the first-ever comprehensive antigen atlas, today announced the appointments of Tara Arvedson, Ph.D., and Janine Schuurman, Ph.D., to its Scientific Advisory Board. With decades of expertise across antibody biology and immuno-oncology drug discovery, Dr. Arvedson and Dr. Schuurman are poised to play a critical role in the ongoing advancement of Cartography’s novel and potentially best-in-class cancer immunotherapies.
Cartography Biosciences Appoints Industry Veteran as Chief Administrative and Legal Officer
Cartography Biosciences, an immuno-oncology company creating biologic therapies against novel targets guided by the first-ever comprehensive antigen atlas, today announced the appointment of Blaine Templeman as Chief Administrative and Legal Officer.
Cartography Biosciences Appoints Chester Wong as VP, Head of Business Development
Cartography Biosciences, a precision medicine company creating therapeutics guided by the first-ever comprehensive single-cell antigen atlas for immuno-oncology targets, today announced the appointment of Chester Wong as Vice President, Head of Business Development. He is a member of Cartography’s executive leadership team.
Cartography Biosciences Launches to Accelerate Precision Immunotherapy with Comprehensive Antigen Profiling
Cartography Biosciences, a precision medicine company creating therapeutics guided by the first-ever comprehensive antigen atlas for immuno-oncology targets, launched today with $57 million in initial funding. 8VC led the company’s Series A financing with strong participation from existing investors Andreessen Horowitz (a16z), which led Cartography’s seed financing, and Wing VC, which was also a seed investor. The Series A financing was joined by new investors Catalio Capital Management, ARTIS Ventures, Alexandria Venture Investments, AME Cloud Ventures, the Cancer Research Institute, and Gaingels. The company plans to use the proceeds to advance a pipeline of therapeutics designed to broaden the reach of next-generation cancer therapies, as well as conduct a breadth of discovery programs designed to identify novel, best-in-class target antigens across a range of cancer indications.
